Oral oxytocin for abdominal pain

Introduction

Chronic abdominal pain is a widespread debilitating condition commonly associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). IBS and IBD affect more than 10% of the global population, leaving a severe and steadily growing socio-economic burden on society (115 billion/year in Europe in direct and indirect health care costs).

Challenges in Pain Management

Adequate pain management for these conditions is imperative but remains challenging since classical analgesics are poorly effective, associated with adverse effects, and can even exacerbate disease progression.

Project Overview

In this project, we will advance a new class of gut-stable peptide analgesics to target abdominal pain at its origin in the gut. This represents a highly innovative treatment strategy with a large safety window due to its gut-specific action and negligible risk of systemic off-target effects.

Addressing Industry Challenges

It also addresses a long-standing problem in the peptide therapeutics industry, namely the lack of oral peptide drugs. The objective of this project is to:

1. Optimise our patented lead compounds towards oral drug candidates.
2. Generate robust and supporting preclinical data for clinical translation.

Proof-of-Concept and Industry Engagement

The proof-of-concept data will then be used to engage with industry partners and other supporters to advance these drug candidates into the clinic for the treatment of chronic abdominal pain.

Potential Impact

Our gut-specific treatment approach along with this new class of analgesics could induce a highly desired paradigm shift in how to treat chronic abdominal pain and gastrointestinal disorders, an area with unprecedented unmet medical need. This could benefit millions of people worldwide, improve their quality of life, and help reduce the substantial socio-economic burden that chronic abdominal pain has on society.